DOCSLIB.ORG

Attachment 1 APPENDIX 1 LIST of GOODS 1.1 Peru's List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Attachment 1 APPENDIX 1 LIST of GOODS 1.1 Peru's List Attachment 1 APPENDIX 1 LIST OF GOODS 1.1 Peru's List Subheading Description Base Rate Basket 0101101000 - - Horses 4 A 0101102000 - - Asses 4 A 0101901100 - - - For racing 12 A 0101901900 - - - Other 12 A 0101909000 - - Other 4 A 0102100000 - Pure-bred breeding animals 0 A 0102901000 - - For fighting 12 A 0102909000 - - Other 12 A 0103100000 - Pure-bred breeding animals 0 A 0103910000 - - Weighing less than 50 kg 12 A 0103920000 - - Weighing 50 kg or more 12 A 0104101000 - - Pure-bred breeding animals 0 A 0104109000 - - Other 12 A 0104201000 - - Pure-bred breeding animals 0 A 0104209000 - - Other 12 A 0105120000 - - Turkeys 12 B 0105190000 - - Other 12 A 0105940000 - - Fowls of the species Gallus domesticus 4 B 0105990000 - - Other 12 A 0106110000 - - Primates 12 A - - Whales, dolphins and porpoises (mammals of the order Cetacea); 0106120000 12 B manatees and dugongs (mammals of the order Sirenia) 0106191100 - - - - Llamas (Lama glama), included guanacos 12 A 0106191200 - - - - Alpacas (Lama pacus) 12 A 0106191900 - - - - Other 12 A 0106199000 - - - Other 12 A 0106200000 - Reptiles (including snakes and turtles) 12 A 0106310000 - - Birds of prey 12 A - - Psittaciformes (including parrots, parakeets, macaws and 0106320000 12 A cockatoos) 0106390000 - - Other 12 A 0106901000 - - Insects 12 A 0106909000 - - Other 12 A 0204100000 - Carcasses and half-carcasses of lamb, fresh or chilled 25 B 0204210000 - - Carcasses and half-carcasses 25 B 0204220000 - - Other cuts with bone in 25 B 0204230000 - - Boneless 25 B 0204300000 - Carcasses and half-carcasses of lamb, frozen 25 B 0204410000 - - Carcasses and half-carcasses 25 B 0204430000 - - Boneless 25 B 0204500000 - Meat of goats 25 B 0205000000 Meat of horses, asses, mules or hinnies, fresh, chilled or frozen. 12 B 0206100000 - Of bovine animals, fresh or chilled 12 B 0206210000 - - Tongues 12 B 0206220000 - - Livers 12 B 0206290000 - - Other 12 B 0206300000 - Of swine, fresh or chilled 17 B 0208100000 - Of rabbits or hares 25 A 0208300000 - Of primates 25 A - Of whales, dolphins and porpoises (mammals of the order Cetacea); 0208400000 25 B of manatees and dugongs (mammals of the order Sirenia) 0208500000 - Of reptiles (including snakes and (sea) turtles) 25 A 0208900000 - Other 25 A 0210910000 - - Of primates 25 A 1 of 99 Subheading Description Base Rate Basket - - Of whales, dolphins and porpoises (mammals of the order 0210920000 25 B Cetacea); of manatees and dugongs (mammals of the order Sirenia) 0210930000 - - Of reptiles (including snakes and (sea) turtles) 25 A 0301100000 - Ornamental fish 12 A 0301911000 - - - For breeding or industrial raising 12 A 0301919000 - - - Other 12 A 0301920000 - - Eels (Anguilla spp.) 12 A 0301930000 - - Carp 12 A 0301940000 - - Bluefin tunas(Thunnus thynnus) 12 A 0301950000 - - Southern bluefin tunas (Thunnus maccoyii) 12 A 0301991000 - - - For breeding or industrial raising 12 A 0301999000 - - - Other 12 A - - Trout (Salmo trutta, Oncorhynchus mykiss, Oncorhynchus clarki, 0302110000 Oncorhynchus aguabonita, Oncorhynchus gilae, Oncorhynchus 12 A apache and Oncorhynchus chrysogaster) - - Pacific salmon (Oncorhynchus nerka, Oncorhynchus gorbuscha, Oncorhynchus keta, Oncorhynchus tschawytscha, Oncorhynchus 0302120000 12 A kisutch, Oncorhynchus masou and Oncorhynchus rhodurus), Atlantic salmon (Salmo salar) and Danube salmon (Hucho hucho) 0302190000 - - Other 12 A - - Halibut (Reinhardtius hippoglossoides, Hippoglossus hippoglossus, 0302210000 12 A Hippoglossus stenolepis) 0302220000 - - Plaice (Pleuronectes platessa) 12 A 0302230000 - - Sole (Solea spp.) 12 A 0302290000 - - Other 12 A 0302310000 - - Albacore or longfinned tunas (Thunnus alalunga) 12 A 0302320000 - - Yellowfin tunas (Thunnus albacares) 12 A 0302330000 - - Skipjack or stripe-bellied bonito 12 A 0302340000 - - Bigeye tunas (Thunnus obesus) 12 A 0302350000 - - Bluefin tunas (Thunnus thynnus) 12 A 0302360000 - - Southern bluefin tunas (Thunnus maccoyii) 12 A 0302390000 - - Other 12 A - Herrings (Clupea harengus, Clupea pallasii), excluding livers and 0302400000 12 A roes - Cod (Gadus morhua, Gadus ogac, Gadus macrocephalus), excluding 0302500000 12 A livers and roes - - Sardines (Sardina pilchardus, Sardinops spp.), sardinella 0302610000 12 A (Sardinella spp.), brisling or sprats (Sprattus sprattus) 0302620000 - - Haddock (Melanogrammus aeglefinus) 12 A 0302630000 - - Coalfish (Pollachius virens) 12 A - - Mackerel (Scomber scombrus, Scomber australasicus, Scomber 0302640000 12 A japonicus) 0302650000 - - Dogfish and other sharks 12 A 0302660000 - - Eels (Anguilla spp.) 12 A 0302670000 - - Swordfish (Xiphias gladius) 12 A 0302680000 - - Toothfish (Dissostichus spp.) 12 A 0302690000 - - Other 12 A 0302700000 - Livers and roes 12 A 0303110000 - - Sockeye salmon (red salmon) (Oncorhynchus nerka) 12 B 0303190000 - - Other 12 B - - Trout (Salmo trutta, Oncorhynchus mykiss, Oncorhynchus clarki, 0303210000 Oncorhynchus aguabonita, Oncorhynchus gilae, Oncorhynchus 12 B apache and Oncorhynchus chrysogaster) 0303220000 - - Atlantic salmon (Salmo salar) and Danube salmon (Hucho hucho) 12 B 0303290000 - - Other 12 B - - Halibut (Reinhardtius hippoglossoides, Hippoglossus hippoglossus, 0303310000 12 B Hippoglossus stenolepis) 0303320000 - - Plaice (Pleuronectes platessa) 12 B 0303330000 - - Sole (Solea spp.) 12 B 0303390000 - - Other 12 B 0303410000 - - Albacore or longfinned tunas (Thunnus alalunga) 12 B 2 of 99 Subheading Description Base Rate Basket 0303420000 - - Yellowfin tunas (Thunnus albacares) 12 B 0303430000 - - Skipjack or strip-bellied bonito 12 B 0303440000 - - Bigeye tunas (Thunnus obesus) 12 B 0303450000 - - Bluefin tunas (Thunnus thynnus) 12 B 0303460000 - - Southern bluefin tunas (Thunnus maccoyii) 12 B 0303490000 - - Other 12 B 0303510000 - - Herrings (Clupea harengus, Clupea pallasii), 12 B 0303520000 - - Cod (Gadus morhua, Gadus ogac, Gadus macrocephalus) 12 B 0303710010 - - - Without head and entrails 12 B 0303710090 - - - Other 12 B 0303720000 - - Haddock (Melanogrammus aeglefinus) 12 B 0303730000 - - Coalfish (Pollachius virens) 12 B 0303750000 - - Dogfish and other sharks 12 B 0303760000 - - Eels (Anguilla spp.) 12 B 0303770000 - - Sea bass (Dicentrarchus labrax, Dicentrarchus punctatus) 12 B 0303780000 - - Hake (Merluccius spp., Urophycis spp.) 12 B 0303800000 - Livers and roes 12 B 0304110000 - - Swordfish (Xiphias gladius) 12 A 0304120000 - - Toothfish (Dissostichus spp.) 12 A 0304190000 - - Other 12 A 0305100000 - Flours, meals and pellets of fish, fit for human consumption 12 B 0305200000 - Livers and roes of fish, dried, smoked, salted or in brine 12 B 0305301000 - - Of cod (Gadus morhua, Gadus ogac, Gadus macrocephalus) 12 B 0305309000 - - Other 12 B - - Pacific salmon (Oncorhynchus nerka, Oncorhynchus gorbuscha, Oncorhynchus keta, Oncorhynchus tschawytscha, Oncorhynchus 0305410000 12 A kisutch, Oncorhynchus masou and Oncorhynchus rhodurus), Atlantic salmon (Salmo salar) and Danube salmon (Hucho hucho) 0305420000 - - Herrings (Clupea harengus, Clupea pallasii) 12 B 0305490000 - - Other 12 B 0305510000 - - Cod (Gadus morhua, Gadus ogac, Gadus macrocephalus) 12 B 0305610000 - - Herrings (Clupea harengus, Clupea pallasii) 12 B 0305620000 - - Cod (Gadus morhua, Gadus ogac, Gadus macrocephalus) 12 B 0305630000 - - Anchovies (Engraulis spp.) 12 B 0305690000 - - Other 12 B - - Rock lobster and other sea crawfish (Palinurus spp., Panulirus spp., 0306110000 12 B Jasus spp.) 0306120000 - - Lobsters (Homarus spp.) 12 B 0306131100 - - - - Whole 12 B 0306131200 - - - - Tails, without caparison 12 B 0306131300 - - - - Tails, with caparison, not cooked by steaming or by boiling water 12 B 0306131400 - - - - Tails, with caparison, cooked by steaming or by boiling water 12 B 0306131900 - - - - Other 12 B 0306139100 - - - - Shrimps 12 B 0306139900 - - - - Other 12 B 0306140000 - - Crabs 12 B - - Other, including flours, meals and pellets of crustaceans, fit for 0306190000 12 B human consumption - - Rock lobster and other sea crawfish (Palinurus spp., Panulirus spp., 0306210000 12 B Jasus spp.) 0306220000 - - Lobsters (Homarus spp.) 12 B 0306231100 - - - - For breeding or industrial raising 12 A 0306231910 - - - - - Fresh or chilled 12 A 0306231990 - - - - - Other 12 B 0306239100 - - - - For breeding or industrial raising 12 B 0306239900 - - - - Other 12 A 0306240000 - - Crabs (excepto macruros) 12 B 0306291000 - - - Flours, meals and pellets 12 A 0306299000 - - - Other 12 A 3 of 99 Subheading Description Base Rate Basket 0307100000 - Oysters 12 A 0307211000 - - - Scallops (“shell of fan”) 12 A 0307219000 - - - Other 12 B 0307291000 - - - Scallops (“shell of fan”) 12 A 0307299000 - - - Other 12 B 0307310000 - - Live, fresh or chilled 12 A 0307390000 - - Other 12 A 0307410000 - - Live, fresh or chilled 12 B 0307490000 - - Other 12 B 0307510000 - - Live, fresh or chilled 12 B 0307590000 - - Other 12 B 0307600000 - Snails, other than sea snails 12 A 0307911000 - - - Sea-urchins 12 A 0307919000 - - - Other 12 A 0307992000 - - - “Locos” (Concholepas concholepas) 12 A 0307993000 - - - Sea cucumber (Isostichopus fuscus) 12 B 0307994000 - - - Sea snails 12 B 0307995000 - - - “Lapas” 12 B 0307999010 - - - - Razor clams (Mesodema donacium) 12 B 0307999090 - - - - Other 12 B 0407002000 - For producing vaccines (free of specific pathogens) 12 A 0410000000 Edible products of animal origin, not elsewhere specified or included. 20 B Human hair, unworked, whether or not washed or scoured; waste of 0501000000 12 A human hair. 0502100000 - Pigs’, hogs’ or boars’ bristles and hair and waste thereof
Load more

Recommended publications
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M
    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Proposed Regulation of the State Board of Pharmacy
    PROPOSED REGULATION OF THE STATE BOARD OF PHARMACY LCB File No. R133-14 Workshop July 24, 2014 NAC 453.540 Schedule IV. (NRS 453.146, 639.070) 1. Schedule IV consists of the drugs and other substances listed in this section, by whatever official, common, usual, chemical or trade name designated. 2. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs, including, without limitation, their salts, calculated as the free anhydrous base of alkaloid, is hereby enumerated on schedule IV, in quantities: (a) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; or (b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxy- butane). 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation which contains any quantity of the following substances, including, without limitation, their salts, isomers and salts of isomers, is hereby enumerated on schedule IV, whenever the existence of such salts, isomers and salts of isomers is possible within the specific chemical designation: Alprazolam; Barbital; Bromazepam; Butorphanol; Camazepam; Carisoprodol; Chloral betaine; Chloral hydrate; Chlordiazepoxide; Clobazam; Clonazepam; Clorazepate; Clotiazepam; Cloxazolam; Delorazepam; Diazepam; Dichloralphenazone; Estazolam; Ethchlorvynol; Ethyl loflazepate; Fludiazepam; Flunitrazepam; --1-- Agency Draft of Proposed Regulation R133-14 Flurazepam; Halazepam; Haloxazolam; Ketazolam; Loprazolam; Lorazepam; Lormetazepam; Mebutamate; Medazepam; Meprobamate; Methohexital; Methylphenobarbital (mephobarbital); Midazolam; Nimetazepam; Nitrazepam; Nordiazepam; Oxazepam; Oxazolam; Paraldehyde; Petrichloral; Phenobarbital; Pinazepam; Prazepam; Quazepam; Tramadol (2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol) Temazepam; Tetrazepam; Triazolam; Zaleplon; Zolpidem; or Zopiclone.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Abecarnil/Allobarbital 959 Pharmacopoeias
    Abecarnil/Allobarbital 959 Pharmacopoeias. In Eur. (see p.vii). acamprosate’s action including inhibition of neuronal hyper- maleate in the treatment of anxiety disorders, hiccups, and nau- Ph. Eur. 6.2 (Acamprosate Calcium). A white or almost white excitability by antagonising excitatory amino acids such as sea and vomiting. Acepromazine, as the base, has also been giv- powder. Freely soluble in water; practically insoluble in alcohol glutamate. en in preparations for the management of insomnia. and in dichloromethane. A 5% solution in water has a pH of 5.5 1. Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacol- Preparations to 7.0. ogy and clinical potential in the management of alcohol depend- ence after detoxification. Drugs 1997; 53: 1038–53. Proprietary Preparations (details are given in Part 3) Adverse Effects 2. Anonymous. Acamprosate for alcohol dependence? Drug Ther Denm.: Plegicil; Turk.: Plegicil. The main adverse effect of acamprosate is dosage-related diar- Bull 1997; 35: 70–2. Multi-ingredient: Fr.: Noctran. rhoea; nausea, vomiting, and abdominal pain occur less frequent- 3. Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry 2001; 62 (suppl ly. Other adverse effects have included pruritus, and occasionally 20): 42–8. a maculopapular rash; bullous skin reactions have occurred rare- 4. Overman GP, et al. Acamprosate for the adjunctive treatment of Aceprometazine (rINN) ly. Depression and fluctuations in libido have also been reported. alcohol dependence. Ann Pharmacother 2003; 37: 1090–9. Hypersensitivity reactions including urticaria, angioedema, and 5. Anton RF, et al. Combined pharmacotherapies and behavioral 16-64 CB; Aceprometazina; Acéprométazine; Aceprometazi- anaphylaxis have been reported very rarely.
    [Show full text]
  • Smumedical Journal
    SMU Medical Journal ISSN : 2349 – 1604 (Volume – 4, No. 1, January 2017) Review Article Indexed in SIS (USA), ASI (Germany), I2OR & i-Scholar (India), SJIF (Morocco) and Cosmos Foundation (Germany) databases. Impact Factor: 3.835 (SJIF) Analytical Aspects with Brief Overview of Depressants Sandeep Kumar1 Nand Gopal Giri2 Ashok Kumar Jaiswal3* Anil Kumar Jaiswal4 1M.Sc. (Forensic Science), LNJN NICFS, New Delhi 110085, 2Assistant Professor, Department of Chemistry, Shivaji College (University of Delhi) Raja Garden, New Delhi 110 027, 3Dept. of Forensic Medicine and toxicology, All India institute of Medical Sciences, New Delhi 110 029.4Assistant Professor, Department of Mathematics, St. Andrew’s PG College, Gorakhpur, UP. *Corresponding author Manuscript received : 30.10.2016 Manuscript accepted: 21.11.2016 Abstract Depressants are drugs that slow down the functions of the central nervous system (CNS). These drugs are used to reduce anxiety and insomnia without drowsiness. The depressants cause relaxed feeling if used in small quantity but cause unconsciousness, vomiting and even death if taken in high quantity. It affects concentration and coordination of a person by slowing down his/ her ability to respond in unexpected situations. These drugs are also attributed for their physiological and psychological effects, eventually in large dose it become lethal. The different 142 SMU Medical Journal, Volume – 4, No. – 1, January, 2017 physical and chemical features of some very often used depressants are discussed in this manuscript. Keyword: Depressant, TLC, UV spectroscopy, HPLC, GLC etc. Introduction The classical depressants are hypnotics (which induce sleep), most antianxiety medicine (diazepam or valium), muscle spasm prevent seizure, but these drugs rapidly develop dependence and tolerance which finally leads to coma and death, so use of these drugs is highly unsafe.
    [Show full text]
  • Comparative Efficacy and Acceptability of Pharmacological Treatments for Insomnia in Adults: a Systematic Review and Network Meta-Analysis (Protocol)
    Cochrane Database of Systematic Reviews Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis (Protocol) De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-anal- ysis. Cochrane Database of Systematic Reviews 2016, Issue 9. Art. No.: CD012364. DOI: 10.1002/14651858.CD012364. www.cochranelibrary.com Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta- analysis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 4 METHODS ...................................... 4 Figure1. ..................................... 5 ACKNOWLEDGEMENTS . 9 REFERENCES ..................................... 10 APPENDICES ..................................... 14 WHAT’SNEW..................................... 18 CONTRIBUTIONSOFAUTHORS . 18 DECLARATIONSOFINTEREST . 18 Comparative efficacy and acceptability of pharmacological treatments for
    [Show full text]
  • Larry Kramer Interview Number
    A PROGRAM OF MIX – THE NEW YORK LESBIAN & GAY EXPERIMENTAL FILM FESTIVAL Interviewee: Larry Kramer Interview Number: 035 Interviewer: Sarah Schulman Date of Interview: November 15, 2003 © 2004 The New York Lesbian & Gay Experimental Film Festival, Inc. ACT UP ORAL HISTORY PROJECT Interview of Larry Kramer November 15, 2003 Tape I 00:07:00 SARAH SCHULMAN: If you could say your name, how old you are, where we are and today’s date? LARRY KRAMER: My name is Larry Kramer. We are in my study, in my lover’s and my house in New Preston, Connecticut. SS: How old are you? LK: I’m 68. SS: Mazel tov. What’s today’s date? LK: That I’ve lasted this long is a major miracle. SS: And today is? LK: November 15th, 2003. SS: Well, Larry, you’ve been interviewed many times and you have a lot to say, and what we really want to do is ask you the questions that you probably have not repeated ad nauseum before and that, maybe, more of an internal conversation from people who were inside ACT UP together. So we’re not going to be asking you these generic questions or things that anybody who is interested can find other places. I just want to ask you a few background questions. When did you family come to this country? LK: My father was born in this country, and his mother was from Russia and no one knows where his father was from. And my mother came when she was four, also from Russia.
    [Show full text]
  • Phencyclidine: an Update
    Phencyclidine: An Update U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse and Mental Health Administration Phencyclidine: An Update Editor: Doris H. Clouet, Ph.D. Division of Preclinical Research National Institute on Drug Abuse and New York State Division of Substance Abuse Services NIDA Research Monograph 64 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administratlon National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20657 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 NIDA Research Monographs are prepared by the research divisions of the National lnstitute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic lnstitute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric lnstitute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D GILBERT J. BOTV N, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Cocaine: Pharmacology, Effects, and Treatment of Abuse
    Cocaine: Pharmacology, Effects, and Treatment of Abuse U. S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Cocaine: Pharmacology, Effects, and Treatment of Abuse Editor: John Grabowski, Ph.D. Division of Clinical Research National Institute on Drug Abuse NIDA Research Monograph 50 1984 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, D.C. 20402 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community. Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY, COHEN M.D. Temple University School of Medicine LosAngeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic Institute National Federation of Parents for Troy, New York Drug Free Youth RICHARD BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates, Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTMAN Langley Porter Neuropsychiatric Institute San Francisco, California Alcohol and Drug Problems Association of North America Washington, D.C. DENISE KANDEL, Ph.D. GILBERT J. BOVTIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V.
    [Show full text]